The DOI matches its Crossref record.
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
Open accessAbstract
The objective of this paper is to investigate the mesothelin expression level to the clinicopathological features, chemoresponse, and to the outcome of patients with epithelial ovarian carcinoma (EOC). Mesothelin mRNA was detected by real-time quantitative reverse-transcription PCR in 139 EOC patients. Clinical characteristics, histopathological items, responses to chemotherapy, progression-free survival (PFS), and overall survival (OS) were recorded. Tumours with advanced stages had higher mesothelin than those with early stages. The chemoresistant patients showed significantly higher mesothelin than did chemosensitive patients (2.81 vs 0.43, P<0.001), irrespective of optimal or suboptimal surgery in those with advanced stages. Highly expressed levels of mesothelin were an independent but poor prognostic factor in the PFS (2.03 (1.23-3.37) P=0.006) and OS (3.72 (1.64-8.45), P=0.002) of the 139 EOC patients in multivariate analysis. In addition, patients in advanced stages with highly expressed mesothelin also had significantly worse OS, regardless of whether they had undergone optimal (13.85 (1.76-125.60), P=0.013) or suboptimal (4.47 (1.83-10.88), P=0.001) debulking surgery in multivariate analysis. Out results provide new evidence that mesothelin expression is associated with chemoresistance and with shorter disease-free survival and worse OS of patients with EOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3672 · Cited by 325
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-106 · Cited by 151
“Evidence suggests that MSLN confers resistance to anoikis in breast cancer [4] and chemotherapy (platinum + cyclophosphamide/paclitaxel) in ovarian cancer [5].”
BackgroundSelf-citationBharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr075 · Cited by 118
Self-citation
Metadata
- Authors
- Cheng, W.-F., Huang, C.-Y., Chang, M.-C., Hu, Y.-H., Chiang, Y.-C., Chen, Y.-L., Hsieh, C.-Y., & Chen, C.-A.
- Venue
- British Journal of Cancer
- Published
- 2009-03-17
- Volume
- 100
- Issue
- 7
- Pages
- 1144-1153
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2003541535
- Cited by
- 170
- References
- 0
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6604964
- The paper
- Cheng, W.-F., Huang, C.-Y., Chang, M.-C., Hu, Y.-H., Chiang, Y.-C., Chen, Y.-L., Hsieh, C.-Y., & Chen, C.-A. (2009). High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604964
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.